All In Biotech

Drug Trial Radar · NCT02704403

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Last checked: Nov 19, 2026Latest source record: Mar 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,157 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

2,157

Actual

Start

Mar 2016

Primary completion

Oct 28, 2020

Study completion Oct 28, 2020

Sponsor

Lead sponsor
GenfitIndustry
Sponsor type
Industry
First posted
Mar 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.

Conditions

  • Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Interventions

  • ElafibranorDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Elafibranor-treated Participants Relative to Placebo Achieving Resolution of Nonalcoholic Steatohepatitis Without Worsening of FibrosisTime frame: Measurement at 72 weeks
  2. Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical OutcomesTime frame: From first randomization up to early termination of the study corresponding to 54 months (54 months being the longest duration for any given participant)

Locations

326 sites in 25 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Digestive Health Specialists of the Southeast

    Dothan, Alabama

  • The Institute for Liver Health

    Chandler, Arizona

  • The Institute for Liver Health

    Glendale, Arizona

  • Banner University Medical Center Phoenix

    Phoenix, Arizona

  • Dignity Health St. Joseph's Hospital

    Phoenix, Arizona

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • Institute for Liver Health

    Tucson, Arizona

  • Adobe Clinical Research, LLC

    Tucson, Arizona

  • The University of Arizona College of Medicine Liver Research Institute

    Tucson, Arizona

  • Liver Wellness Center

    Little Rock, Arkansas

  • GW Research, Inc.

    Chula Vista, California

  • Southern California Research Center

    Coronado, California

  • University of California, San Francisco, Fresno Community Regional Medical Center

    Fresno, California

  • Fresno Clinical Research Center

    Fresno, California

  • University of California, San Francisco, Fresno Community Regional Medical Center

    Fresno, California

  • Scripps Clinic Torrey Pines

    La Jolla, California

  • University of California - San Diego

    La Jolla, California

  • Loma Linda University Medical Center - Transplantation Insitute

    Loma Linda, California

  • VA Long Beach Healthcare System

    Long Beach, California

  • Keck Hospital of USC

    Los Angeles, California

  • Ruane Clinical Research Group Inc.

    Los Angeles, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Gastrointestinal Biosciences Clinical Trials LLC

    Los Angeles, California

  • Veterans Affaires Greater Los Angeles Healthcare System, West LA VA Medical Center

    Los Angeles, California

  • Veterans Affairs Greater Los Angeles Healthcare System

    Los Angeles, California

  • Alliance Clinical Research

    Oceanside, California

  • National Research Institute

    Panorama City, California

  • Alliance Clinical Research

    Poway, California

  • University of California, Davis Medical Center

    Sacramento, California

  • University of California, San Diego Airway Research and Clinical Trials Center

    San Diego, California

  • Medical Associates Research Group, Inc.

    San Diego, California

  • VA San Diego HealthCare System

    San Diego, California

  • Quest Clinical Research

    San Francisco, California

  • Sutter West Bay Hospitals dba California Pacific Medical Center

    San Francisco, California

  • University of California, San Francisco, Medical Center at Parnassus

    San Francisco, California

  • Ventura Clinical Trials

    Ventura, California

  • South Denver Gastroenterology

    Englewood, Colorado

  • Yale University School of Medicine, Section of Digestive Diseases

    New Haven, Connecticut

  • Georgetown University Hospitals

    Washington D.C., District of Columbia

Showing 40 of 326 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.